https://www.selleckchem.com/Androgen-Receptor.html
Published by Elsevier Ltd.BACKGROUND Recent publications have suggested an increased risk of delayed adverse events (DAE) with a smooth, cohesive 20 mg/mL hyaluronic acid filler (HA-V). OBJECTIVE To examine the occurrence of HA-V DAEs and identify patterns and characteristics. METHODS Charts from patients who received HA-V between February 1, 2009 and February 28, 2018 from two clinics were analyzed. RESULTS In 4500 patients who received 9324 treatments with HA-V, 44 DAE's were identified, for a combined incidence of 0.98% per patient,
Like
Comment
Share
